Pamidronic Acid

CHEMBL834 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
235.1 g/mol
LogP
-6.9
Phase
4

The free acid form of pamidronate, sharing the same therapeutic uses.

Молекулярная масса

235,0700 g/mol

LogP

-6,90

TPSA

161,00 Ų

Правило пяти Липинского

Соответствует

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NCCC(O)(P(=O)(O)O)P(=O)(O)O

InChI

InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)

Molecular Formula

C3H11NO7P2

HBD / HBA

6 / 8

Вращаемые Связи

4

Тяжёлые Атомы

13

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

The free acid form of pamidronate, sharing the same therapeutic uses.

Yes, Pamidronic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL834. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 4674. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.